(Reuters) - Canada's Cardiome Pharma Corp said it will cut about 85 percent of its workforce after its partner Merck & Co stopped the development of an oral version of their drug to treat irregular heart rhythm.
The two companies were earlier developing an oral version of vernakalant, a drug to treat chronic atrial fibrillation -- a heart rhythm disorder that can lead to stroke and heart failure.
No comments:
Post a Comment